New biopharmaceutical company, Lumavita AG, created in Basel with a Series A financing of CHF 18m
Tuesday, 02.09.2008

New biopharmaceutical company, Lumavita AG, created in Basel with a Series A financing of CHF 18m

Lumavita AG, a newly-created specialty biopharmaceutical company focusing on antiinfectives for women’s health, announces today that it has raised a Series A financing of CHF18m (€11m).

The lead investors are Atlas Venture, BB Biotech Ventures, and BioMedInvest. Dr. Jürg
Eckhardt and Dr. Gerhard Ries join Dr. Karl Naegler of Atlas on the Board. The
Company also announces the appointment of Nicholas Benedict as CEO.

 

Lumavita AG is focused on worldwide development and commercialization of
innovative treatments for infectious diseases in women’s health. The Company’s
product portfolio includes FemiFect® (pentamycin) a polyene macrolide with a unique
spectrum of coverage for the treatment of vaginitis, and SPK-601, a first-in-class PCPLC
inhibitor for the potential treatment of infections caused by Human Papilloma
Virus and Herpes Simplex Virus. FemiFect® is already approved in Switzerland for
the treatment of vaginitis and Lumavita anticipates an imminent launch. A doseoptimized
formulation of FemiFect® is in Ph IIb clinical development, and SPK-601 is
in Phase I. Lumavita was founded on the expertise of co-founder and Chief Scientific
Officer, Dr Cees Winnips, who has a significant background in development within
the pharmaceutical industry in several therapeutic areas, including antiinfective drugs.

 

Lumavita AG is headquartered in Basle, Switzerland.


For further information:  www.lumavita.com


Lumavita Corporate Office
+41 61 225 4102
infoanti spam bot@lumavitaanti spam bot.com

back to list